Publications by authors named "Yannis Lassoued"
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of lower respiratory infections in children, and a new monoclonal antibody, nirsevimab, was introduced in September 2023 to combat RSV.
- A study was conducted on infants under 12 months old to evaluate the effectiveness of nirsevimab against RSV-bronchiolitis in outpatient settings, involving a comparison between RSV-positive and RSV-negative bronchiolitis patients.
- The findings showed that nirsevimab reduced the risk of RSV-bronchiolitis by 79.7%, indicating its effectiveness in preventing this infection in young children during outpatient care.
In a 15-year pediatric time-series analysis, we showed a rise of invasive Group A streptococcal (iGAS) infections since October 2022, mainly involving pleural empyema, simultaneously to a respiratory virus outbreak. Physicians should be aware of this increased risk of pediatric iGAS infections, especially in settings with intense respiratory viruses' circulation.
View Article and Find Full Text PDF